What triggers this $10 million repurchase authorization?

The Board authorized the program following Aspire-Lakewood's acquisition of Dura Control Systems Corp., which immediately added scale (DCSC generated ~$209.5 million in 2025 revenue and $22.3 million in adjusted EBITDA). Management views the current share price as not reflecting the combined company's financial strength and growth opportunities.

How much of Aspire-Lakewood's equity base could this buyback represent?

With approximately 1.5 million shares outstanding as of September 8, 2026, a $10 million repurchase depends on execution price but could represent roughly 0.5 to 0.7 percent of the share base at typical valuations. The actual impact depends on the speed and price of execution.

Can Aspire-Lakewood cancel or modify this program?

Yes. The filing explicitly states the program has no expiration date and may be suspended or terminated at any time without prior notice. Execution is discretionary and depends on market conditions, share price, capital needs, and other management priorities.

How will Aspire-Lakewood execute the repurchases?

The company may repurchase shares through open market transactions or privately negotiated deals, subject to regulatory requirements (such as SEC Rule 10b-18). Timing and amounts will vary based on market conditions and capital availability.

Does this authorization guarantee a specific return to shareholders?

No. The forward-looking statements in the filing acknowledge that share repurchases may not enhance shareholder value, are subject to change, may not be completed as planned, and could be suspended or discontinued depending on numerous factors including share price, cash flow, debt levels, and other capital priorities.

Why did the Board approve this now, given the DCSC acquisition?

The Board cited strengthened liquidity, robust cash generation from DCSC, strong free cash flow, and confidence in long-term strategy. With adjusted EBITDA at approximately $15.00 per share, management believes current valuations present a favorable opportunity to return capital while continuing to invest in the business.

ASBPW 8-K Filed 2026-09-09 New authorization

Aspire-Lakewood authorizes $10M share repurchase program

Board approves stock buyback expansion, citing confidence in business fundamentals and DCSC acquisition integration.

Authorization$10M

MechanismOpen market or privately negot

What the filing says

Aspire-Lakewood Holdings, Inc. (Nasdaq: ASBP) announced on September 9, 2026 that its Board authorized a $10 million common stock repurchase program. This expanded authorization reflects the Company's confidence in its long-term strategy and strong free cash flow generation, particularly following the acquisition of Dura Control Systems Corp. (DCSC).

With approximately 1.5 million shares outstanding as of September 8, 2026, and adjusted EBITDA of approximately $22.3 million for 2025 (equivalent to approximately $15.00 per share), the Board determined that current market conditions present an opportunistic time to authorize the increased repurchase program. The Board believes the share price does not reflect the Company's financial strength or the contribution of DCSC, which generated revenue of approximately $209.5 million and adjusted EBITDA of $22.3 million for the full year 2025, with continued momentum in the first half of 2026 (revenue of $103.9 million and adjusted EBITDA of $10.5 million).

Repurchases under the program may be made through open market or privately negotiated transactions, subject to regulatory requirements and market conditions. The timing and value of shares repurchased will depend on factors including the Company's performance, capital and liquidity requirements, and other management priorities. The program does not require repurchase of any specific number of shares, has no expiration date, and may be suspended or terminated at any time without prior notice.

the Board authorized a $10 million common stock repurchase program (the "Stock Repurchase Program"). This expanded share repurchase program is effective September 9, 2026. — Aspire Biopharma Holdings, Inc. 8-K filing · View on SEC EDGAR →

What this means

Aspire-Lakewood's $10 million buyback authorization represents a material capital allocation decision by management, which believes the stock is undervalued relative to the combined company's earnings power. With 1.5 million shares outstanding and $22.3 million in adjusted EBITDA, the authorization could theoretically repurchase up to roughly 0.5–0.7 percent of the share base at typical valuations, though actual repurchases depend entirely on market conditions and management discretion. The filing emphasizes that this program carries no obligation, has no expiration, and can be terminated at any time—standard for open-market repurchases. The DCSC acquisition's strong cash generation and the Board's confidence in the combined business form the strategic rationale, though execution and shareholder impact will depend on the timing and price at which shares are actually repurchased.

Frequently asked questions

What triggers this $10 million repurchase authorization?: The Board authorized the program following Aspire-Lakewood's acquisition of Dura Control Systems Corp., which immediately added scale (DCSC generated ~$209.5 million in 2025 revenue and $22.3 million in adjusted EBITDA). Management views the current share price as not reflecting the combined company's financial strength and growth opportunities.
How much of Aspire-Lakewood's equity base could this buyback represent?: With approximately 1.5 million shares outstanding as of September 8, 2026, a $10 million repurchase depends on execution price but could represent roughly 0.5 to 0.7 percent of the share base at typical valuations. The actual impact depends on the speed and price of execution.
Can Aspire-Lakewood cancel or modify this program?: Yes. The filing explicitly states the program has no expiration date and may be suspended or terminated at any time without prior notice. Execution is discretionary and depends on market conditions, share price, capital needs, and other management priorities.
How will Aspire-Lakewood execute the repurchases?: The company may repurchase shares through open market transactions or privately negotiated deals, subject to regulatory requirements (such as SEC Rule 10b-18). Timing and amounts will vary based on market conditions and capital availability.
Does this authorization guarantee a specific return to shareholders?: No. The forward-looking statements in the filing acknowledge that share repurchases may not enhance shareholder value, are subject to change, may not be completed as planned, and could be suspended or discontinued depending on numerous factors including share price, cash flow, debt levels, and other capital priorities.
Why did the Board approve this now, given the DCSC acquisition?: The Board cited strengthened liquidity, robust cash generation from DCSC, strong free cash flow, and confidence in long-term strategy. With adjusted EBITDA at approximately $15.00 per share, management believes current valuations present a favorable opportunity to return capital while continuing to invest in the business.

authorization aspire-biopharma asbpw acquisition dcsc open-market discretionary

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.